Suranga Chandratillake

The transition from founder to venture capitalist is often framed as a logical graduation, but for Suranga Chandratillake, General Partner at Balderton Capital, it was a return to the creative roots of entrepreneurship. Having scaled Blinkx from a two-person operation to a public company with hundreds of millions in revenue, Chandratillake realized that the late-stage CEO role often swaps innovation for optimization. In the world of European venture capital, he now advocates for an ‘artisanal’ approach that rejects the industrialization of the asset class. Why the founder-to-investor pivot requires a mindset reset Many founders believe their operational experience is a direct substitute for investment acumen. However, the psychological shift is seismic. At Blinkx, Chandratillake thrived on solving the fundamental ‘blank page’ problems: defining the commercial model, architecting the technology, and pivoting from general search to video. Once a company reaches a certain scale, the job shifts. It becomes about incremental efficiency, a phase he found far less compelling than the high-stakes creativity of the early days. When he joined Balderton Capital a decade ago, he had to learn that being a great investor means resisting the urge to be the CEO. New investors often over-index on the idea or the market because they see how they would execute it. This is a trap. A great investor recognizes that they are merely the sounding board, not the operator. If you find yourself wanting to do the work for the founder, you have backed the wrong team or you haven't yet mastered the discipline of the check-writer. The Balderton matrix and the hunt for drive Balderton Capital utilizes a rigorous, albeit ‘top secret’, framework to identify the traits of successful founders. This isn't a simple checklist; it is a matrix of often contradictory traits seen in their most successful portfolio companies. While the industry frequently obsesses over rapid-fire term sheets, Chandratillake insists on a process that prioritizes human connection. This process often culminates in informal dinners where the focus shifts away from the P&L and toward personal history. The goal is to understand what has driven an individual to achieve in the past. Because the average venture relationship lasts roughly eight years—statistically similar to the length of many marriages—investors must determine if they can weather the inevitable 'down' cycles with a founder. If the energy and drive aren't there, the most brilliant business model in the world will eventually hit a ceiling. The danger of groupthink in the AI era Venture capital is notoriously susceptible to cycles of hysteria. Whether it was the cloud SAS boom, the crypto wave, or the current AI frenzy, the industry tends to read the same papers and chase the same ‘hot’ deals. Chandratillake notes that there is rarely a strong correlation between the most competitive, over-subscribed initial rounds and the ultimate success of a company. Some of the biggest hits come from contrarian bets that saw zero competition at the seed stage. Staying disciplined means ignoring the noise of what other firms are doing and focusing on the fundamental problem-solving capability of the team. Institutionalizing empathy through the performance platform One of the most significant shifts at Balderton Capital has been the formalization of support for founder well-being. This wasn't a marketing gimmick but an evolution born from data. By surveying both backed and unbacked founders, the firm realized its reputation was anchored in being a ‘holistic partner.’ Building a Unicorn is a marathon, yet the industry often treats it like a two-year sprint. To combat burnout, Balderton launched a dedicated platform focused on performance and well-being. This platform provides modules on physical health, family balance, and peer-to-peer connectivity. Crucially, much of the data is anonymous to the partners. This creates a safe space for CEOs to address the ‘weird journey’ of leadership without fear that their personal struggles will affect their standing with their board. The equal partnership model as a competitive edge Unlike many firms that operate as a collection of individual ‘lone wolves’ under a shared brand, Balderton Capital functions as an equal partnership. Every partner has an equal vote on investments, and every partner shares equally in the economics of the fund. This structure removes the internal ego that often plagues VC firms. If a fintech company is going through a massive technical upheaval, a partner with deep engineering roots can step in to support the primary fintech partner without friction. The founders benefit from a ‘world-class venture in your corner’ approach that combines local European expertise with the resources of a global firm. This model ensures that the help founders receive isn't limited by the specific bandwidth or knowledge of a single board member. Why venture must remain a shoe-leather business There is a growing trend of venture firms scaling into massive, transactional machines. Chandratillake is wary of this trajectory. While there is a financial argument for building a management layer and automating the investment process, it kills the artisanal nature of the work. For him, the value of venture is found in the ‘shoe-leather’ moments: a coffee with a founder in Paris before a train, or a high-stakes whiteboarding session in London when Google launches a competing product. Scale often brings management duties that mimic the late-stage CEO roles he left behind. By capping the number of investments and maintaining a hands-on approach, Balderton Capital aims to keep the job exciting for the partners while providing high-touch service to the founders. It is a commitment to the craft over the machine. Solving for the neglected through AI Looking toward the future, Chandratillake points to Healx, a Cambridge-based startup, as a prime example of the impact-driven innovation he seeks. Healx uses machine learning to identify drug targets for rare diseases—conditions that are often ignored by big pharma because the individual markets are too small. By using AI to make pharmaceutical creativity faster and cheaper, Healx is making it economically viable to treat the millions of people, many of them children, suffering from genetic disorders. This is the ultimate promise of technology: using disruption not just for profit, but to solve problems that were previously deemed unsolvable.